Compare · CMMB vs NVO
CMMB vs NVO
Side-by-side comparison of Chemomab Therapeutics Ltd. (CMMB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMMB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 15067.7x CMMB ($12.7M).
- Over the past year, CMMB is down 65.2% and NVO is down 45.0% - NVO leads by 20.2 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for CMMB).
- NVO has more recent analyst coverage (25 ratings vs 5 for CMMB).
- Company
- Chemomab Therapeutics Ltd.
- Novo Nordisk A/S
- Price
- $1.77-3.28%
- $41.55-3.24%
- Market cap
- $12.7M
- $191.82B
- 1M return
- -1.39%
- -9.30%
- 1Y return
- -65.16%
- -44.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 3
- 8
- Recent ratings
- 5
- 25
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CMMB
- SEC Form 3 filed by new insider Melincoff Gwen A
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 3 filed by new insider Mor George Adi
- SEC Form 3 filed by new insider Darvish Nissim
- SEC Form 3 filed by new insider Cohen Neil Harris
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care